Market Cap 309.86M
Revenue (ttm) 0.00
Net Income (ttm) -42.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 50,800
Avg Vol 209,700
Day's Range N/A - N/A
Shares Out 28.04M
Stochastic %K 33%
Beta 1.29
Analysts Strong Sell
Price Target $22.33

Company Profile

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-30...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 333 5280
Address:
3565 General Atomics Court, Suite 200, San Diego, United States
InvestorWisdom
InvestorWisdom Oct. 16 at 5:09 PM
$CTNM nice chart… biotech play
0 · Reply
Quantumup
Quantumup Oct. 14 at 10:56 AM
RBC Capital reiterated $CTNM Outperform/$25 $BMY RBC Capital said: Though investors are frequently focused on CTNM's promising IPF drug'791, likely given validation around the target from BMY's developmental LPA1Rs in the indication, we expect increasing attention on their other mid-stage pipeline asset, M1 antagonist '307, as key POC data approach in relapsing remitting MS. We had the opportunity to dive deeply into the program through a call with CTNM's team, coming out of which we continue to see solid rationale for '307's mechanism, some indirect clinical validation, and a broad trial design optimized to detect any potential signal - all of which could facilitate success. Though the program is likely higher risk vs. their IPF and MDD studies, we believe demonstration of any disability reversal could be transformative and lead to considerable stock upside, while downside risk is likely low given limited value attributed to the program.
0 · Reply
JarvisFlow
JarvisFlow Sep. 25 at 11:22 AM
Leerink Partners has adjusted their stance on Contineum Therapeutics ( $CTNM ), setting the rating to Outperform with a target price of 20.
0 · Reply
Quantumup
Quantumup Sep. 25 at 11:10 AM
Leerink🏁 $CTNM Outperform/$20: Idiopathic pulmonary fibrosis (IPF) might no longer be a drug development graveyard. There have been two Ph 3 successes in the past year, and $BMY (OP, Risinger) is advancing an LPA1R antagonist in a large Ph 3 program with data expected 2H26. We like CTNM for their fast-follower approach to LPA1R, with the thesis that BMY's admilparant will be first-in-class while CTNM's PIPE-791 will emerge as the best-in-class program with improved pharmacology. Initiate Outperform, PT $20.
0 · Reply
HildredHolcomb1001
HildredHolcomb1001 Sep. 21 at 7:07 AM
$CTNM Medical technology niche. Thin volume trading. No clear pattern emerging. Avoid due to illiquidity.
0 · Reply
Geno412
Geno412 Sep. 18 at 1:26 PM
$CTNM https://www.stocktitan.net/news/CTNM/contineum-therapeutics-reports-positive-topline-data-from-phase-1b-y4lasp4z9eyh.html 🚀🚀🚀🚀🚀 $WOLF $TLRY
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 10 at 2:01 PM
$CTNM Excellent article that nails exactly where CTNM stands right now. So if you want to update your CTNM knowledge or get acquainted with CTNM, this is a must read. https://beyondspx.com/quote/CTNM/analysis/contineum-therapeutics-unpacking-the-pipeline-and-financial-runway-ahead-of-key-data-readouts-ctnm
0 · Reply
rouskejfan
rouskejfan Sep. 10 at 10:42 AM
$CTNM is there any transcript from the fireside chat?
0 · Reply
Eroc
Eroc Sep. 9 at 7:40 PM
$CTNM yessir! We keep climbing! I hope my friends at $ISPC $RGTI are looking at some nice steady climbs instead of just the monster blow ups! $CTNM out climbing both $SPY and $QQQ the past couple of weeks. Let's go bulls!
1 · Reply
tommyrulz
tommyrulz Sep. 8 at 3:00 PM
$CTNM they presented at Morgan Stanley today. Guess they impressed. 🚀
0 · Reply
Latest News on CTNM
InvestorWisdom
InvestorWisdom Oct. 16 at 5:09 PM
$CTNM nice chart… biotech play
0 · Reply
Quantumup
Quantumup Oct. 14 at 10:56 AM
RBC Capital reiterated $CTNM Outperform/$25 $BMY RBC Capital said: Though investors are frequently focused on CTNM's promising IPF drug'791, likely given validation around the target from BMY's developmental LPA1Rs in the indication, we expect increasing attention on their other mid-stage pipeline asset, M1 antagonist '307, as key POC data approach in relapsing remitting MS. We had the opportunity to dive deeply into the program through a call with CTNM's team, coming out of which we continue to see solid rationale for '307's mechanism, some indirect clinical validation, and a broad trial design optimized to detect any potential signal - all of which could facilitate success. Though the program is likely higher risk vs. their IPF and MDD studies, we believe demonstration of any disability reversal could be transformative and lead to considerable stock upside, while downside risk is likely low given limited value attributed to the program.
0 · Reply
JarvisFlow
JarvisFlow Sep. 25 at 11:22 AM
Leerink Partners has adjusted their stance on Contineum Therapeutics ( $CTNM ), setting the rating to Outperform with a target price of 20.
0 · Reply
Quantumup
Quantumup Sep. 25 at 11:10 AM
Leerink🏁 $CTNM Outperform/$20: Idiopathic pulmonary fibrosis (IPF) might no longer be a drug development graveyard. There have been two Ph 3 successes in the past year, and $BMY (OP, Risinger) is advancing an LPA1R antagonist in a large Ph 3 program with data expected 2H26. We like CTNM for their fast-follower approach to LPA1R, with the thesis that BMY's admilparant will be first-in-class while CTNM's PIPE-791 will emerge as the best-in-class program with improved pharmacology. Initiate Outperform, PT $20.
0 · Reply
HildredHolcomb1001
HildredHolcomb1001 Sep. 21 at 7:07 AM
$CTNM Medical technology niche. Thin volume trading. No clear pattern emerging. Avoid due to illiquidity.
0 · Reply
Geno412
Geno412 Sep. 18 at 1:26 PM
$CTNM https://www.stocktitan.net/news/CTNM/contineum-therapeutics-reports-positive-topline-data-from-phase-1b-y4lasp4z9eyh.html 🚀🚀🚀🚀🚀 $WOLF $TLRY
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 10 at 2:01 PM
$CTNM Excellent article that nails exactly where CTNM stands right now. So if you want to update your CTNM knowledge or get acquainted with CTNM, this is a must read. https://beyondspx.com/quote/CTNM/analysis/contineum-therapeutics-unpacking-the-pipeline-and-financial-runway-ahead-of-key-data-readouts-ctnm
0 · Reply
rouskejfan
rouskejfan Sep. 10 at 10:42 AM
$CTNM is there any transcript from the fireside chat?
0 · Reply
Eroc
Eroc Sep. 9 at 7:40 PM
$CTNM yessir! We keep climbing! I hope my friends at $ISPC $RGTI are looking at some nice steady climbs instead of just the monster blow ups! $CTNM out climbing both $SPY and $QQQ the past couple of weeks. Let's go bulls!
1 · Reply
tommyrulz
tommyrulz Sep. 8 at 3:00 PM
$CTNM they presented at Morgan Stanley today. Guess they impressed. 🚀
0 · Reply
Eroc
Eroc Sep. 8 at 2:23 PM
$CTNM yessir! $CTNM
0 · Reply
Eroc
Eroc Sep. 5 at 6:44 PM
$CTNM still looking for $14+ Let's go bulls!
1 · Reply
Eroc
Eroc Sep. 4 at 6:55 PM
$CTNM Analyst Sentiment: Consensus rating: Strong Buy. Average 12-month price target: $22.75, implying potential upside of >110% from today’s level ($10.80)
0 · Reply
Eroc
Eroc Sep. 2 at 8:15 PM
$CTNM Analysts are generally optimistic about CTNM, driven by its robust cash reserves and potentially high-impact trial readouts later this year and into early 2026
1 · Reply
Eroc
Eroc Sep. 2 at 3:33 PM
$CTNM even w/o volume, we still getting 10%+ today. Let's go bulls!
0 · Reply
SynthetixSigma
SynthetixSigma Aug. 23 at 10:28 AM
$CTNM Contineum Therapeutics Inc is a clinical stage neuroscience company with development risks
1 · Reply
Eroc
Eroc Aug. 22 at 2:19 PM
$CTNM imagine if we could get some volume!
1 · Reply
biospeculator
biospeculator Aug. 22 at 1:35 PM
$CTNM Simple question. Is this run-up because of phase II trial results being leaked or a buyout?
1 · Reply
topstockalerts
topstockalerts Aug. 21 at 6:20 PM
$CTNM keep an eye for today......
1 · Reply
Eroc
Eroc Aug. 21 at 6:06 PM
$CTNM no fear amigos! This one is going north! Let's go bulls! We need more chatter on here to bring in some attention to this big mover! $SPY and $QQQ markets are down today, while we are up solid with a strong daily chart!
0 · Reply
Eroc
Eroc Aug. 21 at 3:32 PM
$CTNM yessir! Bounced well off the lows of yesterday and going strong today. Let's go bulls!
0 · Reply
iQuicky
iQuicky Aug. 21 at 3:30 PM
$CTNM this is an interesting stock
0 · Reply